Featured Opinions
New columnists Tina Boggiano & Doug Haggstrom explore pharma's role in digital health.
Building a High-Performance Organization
One of the eternal questions for leaders is: what makes a High-Performance Organization? Lots of companies claim to be High-Performance Organizations. The real thing is rare, however, and instantly recognizable.
Market Segmentation in the New Healthcare Landscape
In order to remain competitive, pharmaceutical companies must shift their focus to smaller, more targeted patient populations.
Pat Andrews has been involved in some major industry contributions over two decades and now faces new opportunities with a pioneering R&D company, Boston Biomedical.
Breakthrough science, not safe science
If we want innovation we must be bolder at what we do, Bernard Munos argues in the first of his new monthly columns for eyeforpharma.
What if We Could Be Heroes, not Villains..
by David Laws
Dale Partridge, founder of Sevenly, is living proof that new, socially conscious business models are not only imminent but also surprisingly profitable. What if valuing people over profit was actually more profitable for pharma?
Leading a Renaissance in Alzheimer's
FORUM Pharmaceuticals CEO and President Deborah Dunsire made the move from the oncology sphere into dementia-related illnesses. She tells Danielle Barron why she likes to stay at the cutting edge of research, while always keeping her eye on the prize – better outcomes for patients.
Chronic Disease Management in China
Patient Self-Management Can Overcome an Important Healthcare Gap
Impactful Presentations in 4 Easy Steps
by Anonymous (not verified)
Working at a business intelligence company, I spend a lot of time at conferences and obviously I come across some stellar presentations. The good news is that's its all entirely coachable.
Selling to IDNs: Strategies for Success
Changes in healthcare delivery are rapidly undermining traditional pharmaceutical commercial models. Customers are fewer and larger as hospitals consolidate into integrated delivery networks in the face of rising cost pressures, stiffer financial penalties and the imperatives of healthcare reform.
Decency as a Driver of Excellence
Dr Nicola Davies speaks to Mette Aagaard Hertz, Corporate Vice President at Novo Nordisk and Head of Human Resources in Research and Development, about pharma’s responsibility to maintain high standards in the fight against global health problems.
Patient centricity – from hubris to humility
In January I was ‘treated’ by 10 HCPs in 7 days and more than 100 patients in 24 hours. The medics managed my physical state; the patients guided my psychological well-being, helping me reach decisions and an understanding more readily by sharing their information and experiences.
Rethinking Pharma Part 3: Why Pharma are Giving Away the Golden Goose
In the 3rd installment of Rethinking pharma, Dr Andree Bates talks about value creation and why she thinks pharma is giving its value away.
Patient Associations are not customers!
by David Laws
With all of the hype and attention around patient centricity and the need to engage patients (customers) in their health, many folks in pharma are rushing to engage with patient associations like never before.
by Marc Yates
One of the brightest emerging market prospects with a model healthcare system… or an overstretched, under-regulated system on the verge of crisis? In this month’s column, I consider both sides of the Colombian story.
by Jeff Elton
As we enter a new year, the focus on real world advanced analytics, value as an expected basis for pricing and reimbursement, and services as a means to value will accelerate.
Insights from the World’s Largest Healthcare Market
New columnist, Jeffrey Frick shares insights on the Chinese healthcare market.
IDNs - What Pharma Needs to Know
One of the most rapidly emerging trends in healthcare is the formation of integrated delivery networks (IDNs). Manufacturers must understand what sets these large networks apart from traditional providers.
Rethinking Pharma Part 2: Why the Clinical Trial Process Must Change
The clinical trial process is a costly and integral part of bringing a drug to market, but does it have to be carried out the way it is currently? Is there a better way?
Adherence Programs: What works?
by Kevin Dolgin
What seperates successful adherence programs from unsuccessful ones?
by Jeff Elton
Investment in real-world data, advanced analytics, and value-delivering services by life sciences companies is growing rapidly, particularly in the US and Europe. These companies are changing their commercial operating models as they attempt to improve patient and health system value outcomes.
Aging in China: The Implications for Healthcare
by Marc Yates
China’s population has aged much faster than other populations, and this rapid aging poses challenges to healthcare, among which the most common are a surging healthcare expenditure and a rising difficulty in managing the 'iron triangle'.
Patients in 2014: the successes, the stories, the surprises
We reflect on the past 12 months from the patient perspective – it has been a phenomenal year of successes, stories and surprises.
Business model innovation won't happen until we do things differently
by David Laws
Customer Centricity, Communities of Practice, Big Data, Patient Centricity (probably), The Digital Organization and many more business model innovations have failed to take serious hold in pharma over the years.
Deirdre Coleman speaks to Pelin Icil, Marketing Manager, Bayer Healthcare (Women’s Health) about what women want and expect from pharma companies and Bayer’s newly launched Women’s Health TV.